Pfizer FY2025 EPS Estimate Increased by Cantor Fitzgerald

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Pfizer in a research report issued on Wednesday, April 30th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will earn $3.10 per share for the year, up from their prior estimate of $2.99. Cantor Fitzgerald currently has a “Neutral” rating and a $24.00 target price on the stock. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share.

PFE has been the topic of a number of other research reports. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.64.

Pfizer Stock Performance

Shares of PFE stock opened at $23.91 on Thursday. Pfizer has a 12-month low of $20.92 and a 12-month high of $31.54. The business’s fifty day simple moving average is $24.39 and its 200-day simple moving average is $25.82. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $135.59 billion, a PE ratio of 16.96, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the business earned $0.82 EPS. The firm’s quarterly revenue was down 7.8% on a year-over-year basis.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.19%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Institutional Trading of Pfizer

Several institutional investors have recently modified their holdings of the stock. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.